According to the ETF Finder at ETF Channel, IRWD makes up 1.29% of the SPDR S&P Biotech ETF (XBI) which is higher by about 0.7% on the day Thursday.
In afternoon trading Thursday, IRWD was down about 1.9% on the day.
Ironwood Pharmaceuticals, Rigel Pharmaceuticals and FibroGen were among the biotech stock movers in premarket trading on Monday.
New bowel drug Trulance will be available for patients later this quarter.
Trade-Ideas LLC identified Ironwood Pharmaceuticals (IRWD) as a weak on high relative volume candidate